This combination approach integrating mild PTT to induce tumor‐selective senescence by using CDK4/6 inhibitors like palbociclib.[31] leveraging the intrinsic HSP70 downregulation in senescent cells, and employing Qu for both HSP70 inhibition and senescent cell clearance represents a rationally designed therapeutic strategy that capitalizes on the complementary advantages of each modality while mitigating their individual limitations, potentially yielding optimized treatment outcomes.[32, 33]. Here, CDK4 is linked to neoplasm.